Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease.
Onouchi Y, Suzuki Y, Suzuki H, Terai M, Yasukawa K, Hamada H, Suenaga T, Honda T, Honda A, Kobayashi H, Takeuchi T, Yoshikawa N, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Murata Y, Ebata R, Higashi K, Ozaki K, Sasago K, Tanaka T, Hata A. Onouchi Y, et al. Among authors: miyawaki m. Pharmacogenomics J. 2013 Feb;13(1):52-9. doi: 10.1038/tpj.2011.45. Epub 2011 Oct 11. Pharmacogenomics J. 2013. PMID: 21987091
A genome-wide association study identifies three new risk loci for Kawasaki disease.
Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, Honda T, Suzuki H, Suenaga T, Takeuchi T, Yoshikawa N, Suzuki Y, Yasukawa K, Ebata R, Higashi K, Saji T, Kemmotsu Y, Takatsuki S, Ouchi K, Kishi F, Yoshikawa T, Nagai T, Hamamoto K, Sato Y, Honda A, Kobayashi H, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Murata Y, Sasago K, Takahashi A, Kamatani N, Kubo M, Tsunoda T, Hata A, Nakamura Y, Tanaka T; Japan Kawasaki Disease Genome Consortium; US Kawasaki Disease Genetics Consortium. Onouchi Y, et al. Among authors: miyawaki m. Nat Genet. 2012 Mar 25;44(5):517-21. doi: 10.1038/ng.2220. Nat Genet. 2012. PMID: 22446962
Variations in ORAI1 Gene Associated with Kawasaki Disease.
Onouchi Y, Fukazawa R, Yamamura K, Suzuki H, Kakimoto N, Suenaga T, Takeuchi T, Hamada H, Honda T, Yasukawa K, Terai M, Ebata R, Higashi K, Saji T, Kemmotsu Y, Takatsuki S, Ouchi K, Kishi F, Yoshikawa T, Nagai T, Hamamoto K, Sato Y, Honda A, Kobayashi H, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Yoshiyama M, Miyashita R, Murata Y, Fujino A, Ozaki K, Kawasaki T, Abe J, Seki M, Kobayashi T, Arakawa H, Ogawa S, Hara T, Hata A, Tanaka T. Onouchi Y, et al. Among authors: miyawaki m. PLoS One. 2016 Jan 20;11(1):e0145486. doi: 10.1371/journal.pone.0145486. eCollection 2016. PLoS One. 2016. PMID: 26789410 Free PMC article.
Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.
Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A. Suzuki H, et al. Among authors: miyawaki m. Pediatr Infect Dis J. 2011 Oct;30(10):871-6. doi: 10.1097/INF.0b013e318220c3cf. Pediatr Infect Dis J. 2011. PMID: 21587094
Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Honda T, Onouchi Y, Terai M, Hata A. Hamada H, et al. Among authors: miyawaki m. Cytokine. 2012 Dec;60(3):681-5. doi: 10.1016/j.cyto.2012.08.006. Epub 2012 Sep 1. Cytokine. 2012. PMID: 22944461 Clinical Trial.
Plasma angiotensin II concentrations in the early neonatal period.
Miyawaki M, Okutani T, Higuchi R, Yoshikawa N. Miyawaki M, et al. Arch Dis Child Fetal Neonatal Ed. 2006 Sep;91(5):F359-62. doi: 10.1136/adc.2005.089573. Epub 2006 Apr 4. Arch Dis Child Fetal Neonatal Ed. 2006. PMID: 16595591 Free PMC article.
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.
Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K; Japanese Study Group of Kidney Disease in Children. Yoshikawa N, et al. Kidney Int. 2015 Jan;87(1):225-32. doi: 10.1038/ki.2014.260. Epub 2014 Jul 23. Kidney Int. 2015. PMID: 25054775 Free PMC article. Clinical Trial.
172 results